Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
2.960
-0.040 (-1.33%)
At close: Nov 20, 2024, 4:00 PM
2.900
-0.060 (-2.03%)
Pre-market: Nov 21, 2024, 5:48 AM EST
Galmed Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 3.76 | 3.92 | 4.66 | 5.66 | 4.13 | 4.2 | |
Research & Development | 3.03 | 3.57 | 13 | 27.22 | 26.08 | 18.18 | |
Operating Expenses | 6.79 | 7.49 | 17.65 | 32.88 | 30.21 | 22.38 | |
Operating Income | -6.79 | -7.49 | -17.65 | -32.88 | -30.21 | -22.38 | |
Interest & Investment Income | 0.38 | 0.38 | 0.3 | 0.56 | 1.19 | 1.95 | |
Currency Exchange Gain (Loss) | -0.04 | -0.04 | 0.04 | -0.03 | -0.12 | -0.11 | |
Other Non Operating Income (Expenses) | -0.13 | -0.01 | -0.02 | -0.04 | -0.03 | -0.03 | |
EBT Excluding Unusual Items | -6.58 | -7.16 | -17.34 | -32.39 | -29.17 | -20.57 | |
Gain (Loss) on Sale of Investments | 0.25 | 0.25 | -0.53 | -0.08 | 0.4 | 0.11 | |
Pretax Income | -6.32 | -6.91 | -17.87 | -32.47 | -28.77 | -20.46 | |
Net Income | -6.32 | -6.91 | -17.87 | -32.47 | -28.77 | -20.46 | |
Net Income to Common | -6.32 | -6.91 | -17.87 | -32.47 | -28.77 | -20.46 | |
Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | |
Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | |
Shares Change (YoY) | 136.81% | 65.23% | 2.22% | 15.59% | 0.79% | 16.41% | |
EPS (Basic) | -11.32 | -29.95 | -127.90 | -237.59 | -243.35 | -174.43 | |
EPS (Diluted) | -13.19 | -30.00 | -127.90 | -237.60 | -243.35 | -174.43 | |
Free Cash Flow | -4.81 | -6.14 | -18.51 | -32.9 | -26.33 | -14.95 | |
Free Cash Flow Per Share | -8.60 | -26.59 | -132.48 | -240.78 | -222.72 | -127.44 | |
EBITDA | -6.7 | -7.46 | -17.62 | -32.84 | -30.17 | -22.34 | |
D&A For EBITDA | 0.09 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | |
EBIT | -6.79 | -7.49 | -17.65 | -32.88 | -30.21 | -22.38 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.